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Abstract
Background: CD44, a hyaluronan (HA) receptor, is a multistructural and multifunctional cell surface molecule
involved in cell proliferation, cell differentiation, cell migration, angiogenesis, presentation of cytokines, chemokines
and growth factors to the corresponding receptors, and docking of proteases at the cell membrane, as well as in
signaling for cell survival. The CD44 gene contains 20 exons that are alternatively spliced, giving rise to many CD44
isoforms, perhaps including tumor-specific sequences.
Methods: Reverse transcriptase polymerase chain reaction (RT-PCR) and Western blotting were used to detect
CD44st mRNA and CD44 protein in sensitive MCF-7, Lovo, K562 and HL-60 cell lines as well as their parental
counterparts, respectively. The full length cDNA encoding CD44st was obtained from the total RNA isolated from
MCF-7/Adr cells by RT-PCR, and subcloned into the pMD19-T vector. The CD44st gene sequence and open reading
frame were confirmed by restriction enzyme analysis and nucleotide sequencing, and then inserted into the
eukaryotic expression vector pcDNA3.1. The pcDNA3.1-CD44st was transfected into MCF-7 cells using
Lipofectamine. After transfection, the positive clones were obtained by G418 screening. The changes of the MMP-2
and MMP-9 genes and protein levels were detected by RT-PCR and gelatin zymography, respectively. The number
of the cells penetrating through the artificial matrix membrane in each group (MCF-7, MCF-7+HA, MCF-7/neo,
MCF-7/neo+HA, MCF-7/CD44st, MCF-7/CD44st+HA and MCF-7/CD44st+Anti-CD44+HA) was counted to compare
the change of the invasion capability regulated by the CD44st. Erk and P-Erk were investigated by Western blotting
to approach the molecular mechanisms of MMP-2 and MMP-9 expression regulated by the CD44st.
Results: Sensitive MCF-7, Lovo, K562 and HL-60 cells did not contain CD44st mRNA and CD44 protein. In contrast,
the multidrug resistance MCF-7/Adr, Lovo/Adr, K562/Adr and HL-60/Adr cells expressed CD44st mRNA and CD44
protein. The CD44st mRNA gene sequence was successfully cloned into the recombinant vector pcDNA3.1 and
identified by the two restriction enzymes. It was confirmed that the reconstructed plasmid contained the gene
sequence of CD44st that was composed of exons 1 to 4, 16 to 17, and 1 to 205 bases of exons 18. The new gene
sequence was sent to NCBI for publication, and obtained the registration number FJ216964. The up-regulated level
of the mRNA of the CD44 gene and the CD44 protein were detected, respectively, by RT-PCR and flow cytometry
in MCF-7 cells transfected with pcDNA3.1-CD44st. The invasiveness of the cells and the activity of MMP-2 and
MMP-9 were clearly activated by HA treatment, and blocked by CD44 neutralizing antibody. MCF-7/CD44st cells
pretreated with the neutralizing antibody against CD44, and the inhibitor of MAPKs signaling pathway, could
strongly block the expression of P-Erk.
Conclusions: A new CD44st was expressed in multidrug resistant MCF-7/Adr, Lovo/Adr, K562/Adr and HL-60/Adr
cells. The expression vector pcDNA3.1-CD44st was cloned and constructed successfully, and stably transfected into
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Background
Tumor invasion is one of the major factors contributing
to patient mortality during disease progression. When a
tumor cell metastasizes, it initially penetrates the sur-
roundings of the extracellular matrix (ECM), invades the
vascular system, and transports to distant sites of the
body [1].
The CD44 gene, which is located on human chromo-
some 11p, contains 20 exons and spans 50 kb. There
are four distinct and characteristic regions in the CD44
protein: the leader peptide-encoding exon (exons 1-5)
LP, the juxtamembranous extracellular variable domain
(exons 6-14), the transmembrane-encoding exon (exon
17) TM, and the cytoplasmic domain (exons 18-20) CT
[2,3] (Figure 1). By selective splicing, the cell-surface gly-
coprotein CD44 can theoretically generate approxi-
mately 800 isoforms [4].
Currently, dozens of CD44 isoforms have been dis-
covered. The standard CD44 (CD44s) is the most com-
mon form, in which exon 5 is directly connected to
exon 16, and lacks the entire variant exon region [1].
In our study, we used MCF-7/Adr cells to clone the
novel CD44st, which contains exons 1 to 4, exons 16
to 17, and 1 to 205 bp of 18 exons (Figure 1). We
found that HA-CD44st signaling leads to activation of
MMP-2 and MMP-9 secretion in the MCF-7/CD44st
cells, and subsequently increases a tumors’ invasion
capability [5,6].
The type I transmembrane glycoprotein receptor
CD44 is a cell membrane receptor that links hyaluronate
to the cytoskeleton ankyrin to mediate signal transduc-
tion [7]. CD44 also plays a role in cell migration, differ-
entiation, and survival signaling, which is important
both to normal cells and cancer cells. An animal model
experiment has demonstratedt h a tb l o c k i n gC D 4 4w i t h
antibodies and antisense oligonucleotides decreases the
malignant activities of the tumor [8]. The intracellular
region of short tail CD44 (CD44st) contains exons 18
and 20, which is potentially linked to the ability of
cytoskeleton protein (ankyrin and actin) to mediate sig-
nal transduction [9,10]. However, whether short tail
CD44 (CD44st) is involved in signal transduction is cur-
rently unclear. Jiang H found that CD44st was not able
to mediate the endocytosis process of the HA based on
the fact that CD44st does not help HA integrate on the
cell membrane [11].
HA, which has a high molecular weight, is widely dis-
tributed in the extracellular matrix (ECM), and could
potentially combine with CD44 and participate in cell
migration and cancer progression [12]. HA plays a role
in anti-angiogenesis, but the degradation products of
HA stimulate the generation of endothelial cells,
Figure 1 The new CD44st mRNA and other CD44 isoforms. The filled circles represent constant regions. The areas circled represent exons
selected for splicing that potentially give rise to many variable isoforms. The cytoplasmic domain of CD44 may bond to the cytoskeleton. The
central region of the CD44 molecule mediates lymphocyte homing and the amino-terminal region links to the HA. The cytoplasmic domain, the
transmembrane region, and HA binding region are highly conserved.[9-10, 19]. B) (1) Standard CD44, which lacks the entire variable region. (2)
pMeta-1; Exons v4 to v7 were inserted in turn into the intermediate part of exons 5 and 17. (3) pMeta-2; Exons v6 and v7 were interposed
between exons 5 and 17 [4]. DNA sequencing confirmed that the reconstructed plasmid contained the sequence of the CD44st gene, which
was composed of exons 1 to 4, exons 16 to 17, and 1 to 205 bases of 20 exons (Figure 1). The new gene sequence was sent to the National
Center for Biotechnology Information (NCBI) for publication and registered with the number FJ216964.
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Page 2 of 11angiogenesis and migration, resulting in CD44 receptor
activation [13]. It has been previously demonstrated that
HA synthase-1 may facilitate bladder cancer metastasis
and therefore could potentially serve as a diagnostic
marker [14].
Matrix metalloproteinases (MMPS) are zinc-required
matrix-degrading enzymes th a tp l a ya ni m p o r t a n tr o l e
in tumor cell metastasis [15]. Recent studies have shown
that hyalurinan strongly activates MMP-2 secretion; the
principal reason is due to CD44 expression [16]. It has
been demonstrated that MMP-9-CD44-EGFR interac-
tion and the dimerization of the MMP-9 hemopexin
domain are critical to the migration of fibrosarcoma
cells [17]. Thus, it appears that HA, CD44, and MMPS
are all involved in the initiation of tumor invasion and
are attractive targets for tumor therapy.
Methods
Reagents and Cell Culture
Fetal bovine serum was purchased from Hangzhou Sijiq-
ing Biological Engineering Materials Co, Ltd. The follow-
ing reagents used in this study were purchased from
Invitrogen: 1640 medium, 2.5% trypsase with EDTA, Tri-
zol, opti-MEM-I Reduced Serum Medium (OPTI-MEM),
Lipofectamine 2000 and G418. The RT-PCR kit was pur-
chased from Fermentas. Hyaluronan was purchased from
Sigma. Matrigel was purchased from Becton Dickinson
and Company. Transwell was purchased from Corning,
and the FITC labeled CD44 antibody used for detection
of flow cytometry was purchased from eBioscience. The
CD44 antibody used for western blot detection was pur-
chased from Abcam. The CD44 blocking antibody was
obtained from Neromarker. Manumycin A, PD98059,
Phospho-p44/42 MAPK (Thr202/Tyr204) Mouse mAb,
and p42 MAP Kinase (Erk) Antibody were purchased
from Cells singnal technology. The recombinant vector
pcDNA3.1 was generously supplied by Dr. XU Wen-rong
in the medical college of Jiangsu University. Human
breast cancer cell lines (MCF-7 and MDR derivative
MCF-7/Adr) and human colorectal cancer cell lines
(Lovo and MDR derivative Lovo/Adr), human promyelo-
cytic leukemia cell lines (HL-60 and MDR derivative HL-
60/Adr), and human chronic myeloid leukemic cell lines
(K562 and MDR derivative K562/Adr) were all obtained
from the Shang-hai cell repository of Academia Sinica
and the cells were maintained in 1640 medium with 10%
heat-inactivated FBS at 37°C in a humidified atmosphere
containing 5% CO2.
Construction and expression of eukaryotic expression
vector pcDNA3.1-CD44st, RNA extraction, and reverse
transcription-PCR
The total RNA of the cultured cells was extracted using
Trizol reagent according to the manufacturer’s
directions. The RT-PCR kit was used to carry out RT-
PCR of each RNA template according to the manufac-
turer’s instructions. In brief, reverse transcription of
each mRNA transcript occurred during incubation for 5
minute at 70°C, followed by incubation for 1 hour at 42°
C and finally at 70°C for 10 minute. The primers of the
CD44 (GenBank.NO.AJ251595) are as follows: forward
primer, 5’-GGATGGACAAGTTTTGGTGGCACG-3’;
reverse primer, 5’-GGTTACACCCCAATCTT-
CATGTCC-3’. PCR amplification for CD44st occurred
as follows: incubation at 94°Cfor 5 minute, 30 cycles at
94°C for 30 seconds, incubation at 66°Cfor 30 seconds,
and at 72°C for 2 minute, followed by incubation at 72°
C for 10 minute, and storage at 4°C. The b-actin gene
primers which were used as a control are as follows: for-
ward primer, 5’-CTCGCGCTACTCTCTCTTTC-3’,
reverse primer, 5’-CATGTCTCGATCCCACTTAAC-3’.
Reverse transcription occurred as above, and PCR
amplification as follows: incubation at 94°C for 5 min-
ute, 30 cycles at 94°C for 30 seconds, incubation at 58°C
for 30 seconds, and at 72°C for 30 seconds, then at 72°C
for 10 minutes, followed by storage at 4°C. PCR amplifi-
cation for MMP-2 (GeneBank accession no. NM
004530) (forward primer, 5’-CGGTGCCCAAGAATA-
GATG-3; reverse primer, 5’-AAAGGAGAAGAGCCT-
GAAGTG-3’) occurred as follows: incubation at 94°C
for 5 minute, followed by 30 cycles at 94°C for 30 sec-
onds, then incubation at 59.1°C for 30 seconds, and
incubation at 72°C for 30 seconds, followed by incuba-
tion at 72°C for 10 minutes, and storage at 4°C. MMP-9
(GeneBank accession no. NM 004994) (forward primer,
5’-CGGAGCACGGAGACGGGTAT-3’; reverse primer
5’-GCCGCCACGAGGAAAACT-3’) PCR amplification
occurred as follows: incubation at 94°C for 5 minute,
followed by 30 cycles at 94°C for 30 seconds, incubation
at 62.7°C for 30 seconds, and at 72°C for 45 seconds,
followed by incubation at 72°C for 10 minute, and sto-
rage at -20°C.
Gene clone and Plasmid construction
The CD44st mRNA extracted from MCF-7/Adr cells via
reverse transcription-PCR was sub-cloned to synthesize
the full-length human CD44st cDNA. The EcoRI and
KpnI restriction sites were incorporated into the forward
and reverse primers as follows: CD44st (EcoR I) forward
primer 5’-GGGAATTCATGGACAAGTTTTGGTGG-
CACG-3’, and CD44st (Kpn I) reverse primer 5’-
GGGGTACCTTACACCCCAATCTTCATGTCC-3’.
The GenBank accession number and product amplifica-
tion protocol of CD44st mRNA are listed above.
According to the manufacturers’ instructions, the PCR
products were visualized by ethidium bromide staining
and subcloned into the pMD19-T vector (Figure 2A).
Plasmid isolation from recombinant E. coli was carried
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gen) according to the manufacturers’ instructions, and
then double digested with EcoRI and KpnI restriction
enzymes and confirmed by DNA sequencing. Next, the
CD44st gene was inserted into the eukaryotic expression
vector pcDNA3.1 (Figure 2B).
Transfection and obtaining the positive clone
The pcDNA3.1 and the pcDNA3.1-CD44st vectors were
transferred to MCF-7 cells according to the manufac-
turers’ protocol. After incubation for 48 hours, the
transfected cells were replanted and exposed to G418
containing medium (800 μg/ml) for 1 week. When a
large number of the cells appeared to be dying, the con-
centration of G418 was reduced to 200 μg/ml and the
cells were incubated for 2 weeks. The positive clones
were identified and selected for further development,
and then cultured with a 200 μg/ml G418 solution to
maintain resistance. The expression of CD44st was con-
firmed by RT-PCR, DNA sequencing, and flow cyto-
metric analysis.
Flow cytometric analysis
Cells in the logarithmic phase were harvested via the
cell scraper technique. After being washed three times
with a PBS solution, the harvested cells were blown uni-
formly into PBS buffer to prepare a single-cell suspen-
sion. 5 × 10
5 cells/ml were incubated with the FITC
conjugated rabbit antimouse antibody for 1 hour at 4°C,
centrifuged at 1000 rpm for 5 min, and then the super-
natant was discarded and cells were resuspended with
500 μL PBS. The relative fluorescence intensity was
detected using the flow cytometer (Becton Dickinson).
T h ed a t aw e r ea n a l y s e dw i t hC e l lQ u e s ts o f t w a r e .T h e
experiment was repeated three times.
The effects of CD44st on the invasion ability of MCF-7
cells
Treatment of Cells
The cells were digested by 0.25% trypsin in combination
with 0.02% EDTA, and then 1.5 × 10
6 cells were seeded
into a new culture flask and diluted with 1.5 ml 1640
medium without heat-inactivated 10% FBS. The cells
pretreated with CD44 blocking antibody were incubated
for 3 hours with serum-free medium containing CD44
blocking antibody (20 μg/ml). HA (100 μg/ml) was
added to the HA treatment groups and the cells were
then incubated for 24 hours. In order to eliminate
potential contamination by growth factor, the HA solu-
tion was boiled at 100°C for 5 minutes before use [18].
Invasion assays by Matrigel
The transwell method (Corning) was used to perform
invasion assays. The pretreatment filters (8 μmp o r e -
size, Matrigel 100 μg/cm
2) were rehydrated with 100 μl
of medium. 1 × 10
5 cells in the volume of 100 μlm e d -
ium were seeded onto the upper part of each well. The
v o l u m eo f1m ls e r u m - f r e e1 6 4 0m e d i u mc o n t a i n i n g
0.1% BSA was added to the lower compartment of the
transwell. After incubation for 24 h at 37°C, the cells
located upon the membranes were wiped with the cot-
ton buds. The cells that had invaded the lower part of
the transwell were stained with the gentian and counted
using light microscopy (×200, 5 random fields). The
invasion capability of the tumor cells was determined by
Figure 2 Construction of recombinant plasmid and pcDNA3.1 vector.. A) 1% Agarose DNA gel electrophoresis for three positive TA clone
plasmids digested by restriction enzyme EcoR I and Kpn I; lane 1 to lane 3: three positive TA clone plasmids; lane M: DL-3000 marker. B) 1%
Agarose DNA gelelectrophoresis for pcDNA3.1-CD44st digested with two restriction enzymes: EcoR I and Kpn I; lane 1 to lane 3: three positive
plasmids, respectively; lane M: DL-10000 Marker.[9,10,19]. B) (1) Standard CD44, which lacks the entire variable region. (2) pMeta-1; Exons v4 to v7
were inserted in turn into the intermediate part of exons 5 and 17. (3) pMeta-2; Exons v6 and v7 were interposed between exons 5 and 17 [4].
DNA sequencing confirmed that the reconstructed plasmid contained the sequence of the CD44st gene, which was composed of exons 1 to 4,
exons 16 to 17, and 1 to 205 bases of 20 exons (Figure 2). The new gene sequence was sent to the National Center for Biotechnology
Information (NCBI) for publication and registered with the number FJ216964.
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of the microscopic fields.
Gelatin Zymography
Gelatin zymography analysis was performed on 20 μl
culture medium per sample according to the manufac-
turers’ protocol. The positive control was a 1:1 ratio of
whole human blood and 2 × non-denaturing loading
buffer.
Western Blot Analysis
3×1 0
5 MCF-7/CD44st cells were seeded in wells of a
6-well plate, grown under routine conditions, and har-
vested at 80-90% confluence. Each sample was resus-
pended in 60 μlo fb o i l i n g2×l o a d i n gb u f f e r .T h e
activation of ERK was detected with a specific antibody
to the phosphorylated form of ERK. After cells were
lysed by sonication, the cell lysate was subjected to cen-
trifugation at 12,000 × g for 15 min at 4°C. The gels
were electro-transferred using an electrophoresis appa-
ratus (Bio-Rad). The total protein of 20 μl/lane was iso-
lated using 10% SDS-PAGE and transferred to a
nitrocellulose transfer membrane (0.2 μm). A 5% non-
fat milk solution with TBST was used to block the
membrane for 1 hour at room temperature. The mem-
brane was incubated with primal mouse anti-human
monoclonal antibody (1:500) at 4°C overnight, washed
with eluant three times within 30 minutes, incubated
with secondary goat anti-rat monoclonal antibody
(1:2000) for 1 h at room temperature, and finally washed
as above. Immunoblots were visualized using a DAB col-
oring reagent kit according to the manufacturers’ proto-
col. Gelatin zymography was performed to determine
the activity level of MMPs in the culture medium.
Statistical analysis
Data were all presented as mean ± standard deviation
(SD). To test for statistical significance, experimental
data were analysed by One-Way ANOVA and SNK-q
test. A p value less than 0.05 was considered to indicate
a statistically significant result. All of the experiments
were repeated in triplicate.
Results
CD44st is expressed in multidrug resistant cells, but not
in parental, sensitive cell lines
We chose the (MDR) cell lines and their respective P-
glycoprotein-negative, drug-sensitive, parental cell lines
in order to study the relationship between CD44st
expression and multidrug resistance by RT-PCR and
Western blot analysis. As s h o w ni nF i g u r e3A - B ,b o t h
CD44st mRNA and CD44 protein were not expressed in
the sensitive MCF-7, Lovo, K562, and HL-60 cell lines.
In contrast, the corresponding multidrug resistant cell
lines all expressed CD44st mRNA and CD44 protein.
This result suggests that a functional link between
CD44st expression and MDR may exist.
Expression of CD44st gene and protein in MCF-7/CD44st
cells
The expression of CD44st mRNA and CD44 protein in
MCF-7/CD44st cells (MCF-7 cells transfected with
pcDNA3.1-44st), MCF-7 cells, and MCF-7/neo cells
(MCF-7 cells transfected with pcDNA3.1) were detected
using RT-PCR and flow cytometry analysis, respectively.
Among these cell lines, only MCF-7/CD44st cells
expressed a high level of CD44st mRNA transcripts and
CD44 protein (Figure 4, 5). As shown in Figure 5, the
mean percentage of CD44 protein expressed was (8.87 ±
1.5)% in MCF-7 cells, (8.17 ± 1.2)%in MCF-7/neo cells,
and (69.8 ± 2.3)% in MCF-7/CD44st cells. There were
no major differences between MCF-7 and MCF-7/neo
cells regarding CD44 expression. We then compared
MCF-7/CD44st cells with MCF-7 or MCF-7/neo cells,
and statistical analysis demonstrated significant differ-
ences in CD44 expression (P < 0.01). This result indi-
cated that the cells transfected stablely with pcDNA3.1-
CD44st were constructed successfully.
MMP-2 and MMP-9 gene expression in MCF-7/CD44st
cells pretreated with HA
Using MCF-7/CD44st cells, we next examined the effect
of HA treatment on MMP-2 and MMP-9 secretion.
Cells were incubated in serum-free medium for 3 h in
the presence or absence of HA. After incubation for 24
h, cells in each group were collected and the expression
levels of interest were detected using RT-PCR. Mean-
while, the culture medium was examined with zymogra-
p h y .A si ss h o w ni nF i g u r e6a n d7 ,M C F - 7 / C D 4 4 s t
cells secreted MMP-2 and MMP-9 in the presence of
HA, and HA pretreatment activated the secretion,
whereas the other groups did not secrete detectable
amounts of MMP-2 and MMP-9 nor respond to the HA
treatment. These results suggest that HA and CD44st
not only induce an increase in the secretion of MMP-2
and MMP-9, but they also are involved in MMP-2 and
MMP-9 activation in MCF-7/CD44st cells. Furthermore,
it is noteworthy that the CD44 blocking antibody was
able to prevent MMP-2 and MMP-9 secretion in MCF-
7/CD44st cells.
CD44st and hyaluronan interaction causes increase of
invasion in MCF-7/CD44st cells
A transwell experiment with pretreatment filters was
used to study the influence of the expression of CD44st
on the invasion of tumor cells. Each group was loaded
onto the upper compartment of the transwell. Cells that
penetrated the membranes were counted. As shown in
F i g u r e8 ,t h en u m b e ro fi n v a s i v ec e l l si nt h eM C F - 7 /
CD44st+HA group occurred at a higher rate compared
to the other experimental groups (p < 0.05). There were
no statistically significantd i f f e r e n c e sa m o n gM C F - 7 ,
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CD44st groups (p > 0.05). After MCF-7/CD44st cells
were pretreated with a CD44 blocking antibody, the
number of cells able to penetrate the membranes
decreased (p < 0.05). This indicated that the invasiveness
of MCF-7/CD44st cells was clearly activated after being
treated with HA. Moreover, the invasiveness of MCF-7/
CD44st cells was significantly suppressed by pretreat-
ment with CD44 blocking antibody. Furthermore, there
was no statistical difference in the number of the cells
Figure 3 CD44st differentially express in sensitive and MDR cancer cells. A) The expression of CD44st in various human cancer cell lines.
Total RNA from sensitive and drug-resistant cells was analyzed using CD44st semi-quantitative RT-PCR. The ß-actin gene was amplified using
semi-quantitative RT-PCR and used as a control. RT-PCR products were run on a 1% agarose gel to show the expression levels of the CD44st
gene and ß-actin gene. The CD44st gene in these cells was also tested by DNA sequencing. B) Cell lysates from sensitive and drug-resistant cells
were immunoblotted with an anti-CD44 antibody.
Figure 4 Expression of CD44st in MCF-7, MCF-7/neo, and MCF-7/CD44st cells. RT-PCR products were run on an agarose gel to indicate the
expression levels of the CD44st gene and b-actin gene. The anticipated 1023-bp product for CD44st was present in MCF-7/CD44st cells. The b-
actin gene was amplified using semi-quantitative RT-PCR and used as a loading control. The 330-bp product for b-actin gene expression was
present in all cells.
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with HA. These results suggest that the activation of
tumor invasiveness relies on the link between HA and
CD44st.
Ras-MAPK signaling pathway plays a role in HA-induced
MMP-2 and MMP-9 secretion in MCF-7/CD44st cells
Previous evidence has suggested that the conjugation of
the HA-CD44 receptor could activate the MAPK signal-
ing pathway [18]. Therefore, we presumed that the
novel alternative splicing clone CD44 may have a func-
tional relationship with the pathway. Therefore, we stu-
died the effect of the HA®CD44st®ras®erk signaling
pathway on HA-induced MMP-2 and MMP-9 secretion.
As is shown in Figure 9A, pretreatment of the cells with
MAPK inhibitors (manumycin A and PD98059) signifi-
cantly suppressed HA-induced MMP-2 and MMP-9
secretion. Moreover, we investigated the role of a CD44
blocking antibody regarding the expression of MMP-2
and MMP-9. As expected, after pretreatment with CD44
blocking antibody, MCF-7/CD44st cells exhibited signifi-
cantly reduced MMP-2 and MMP-9 secretion, which
was examined by gelatin zymogram analysis. These
results clearly indicated that CD44st participation is
necessary for secretion of MMP-2 and MMP-9 to be
activated by HA. To verify this observation, we exam-
ined the expression of ERK and phosphorylated ERK in
MCF-7/CD44st cells. Indeed, we found that HA stimula-
tion up-regulated the phosphorylated ERK in MCF-7/
CD44st cells. In contrast, ERK activation was signifi-
cantly reduced in MCF-7/CD44st cells pretreated with
CD44 blocking anti-bodies, manumycin A and PD98059
(Figure 9B). These results demonstrate that the
CD44st®ras®MAPK pathway is involved in the HA-
induced activation of MMP -2 and MMP-9 secretion.
Discussion
In this study, we determined that CD44st mRNA tran-
scripts and CD44 protein were highly expressed in the
multidrug resistant cell line cells, but not in the parental
Figure 5 Expression of the CD44 protein in MCF-7, MCF-7/neo, and MCF-7/CD44st cells. Flow cytometric analysis was used to examine the
expression level of CD44 protein in MCF-7, MCF-7/neo, and MCF-7/CD44st cells.
Figure 6 Expression of CD44st and expression of HA inducting MMP-2, MMP-9 mRNA. Cells treated with HA were cultured in serum free
medium containing or without HA (100 μg/ml) for 24 h. The expression levels of MMP-2 and MMP-9 mRNA were measured by RT-PCR.
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functional link between CD44st and multidrug resis-
tance. Additionally, we studied the function of the new
CD44 isoforms (GeneBank NO. FJ216964) regarding
tumor invasion using gelatin zymography and transwell
experiments. Our findings indicated that the invasive-
ness of MCF-7/CD44st cells was clearly activated upon
treatment with HA. Moreover, the invasiveness of MCF-
7/CD44st cells was significantly suppressed by pretreat-
ment with CD44 blocking antibody. Furthermore, statis-
tically significant differences in the number of cells
located in the lower compartment of the transwell
experiment did not occur between the group of MCF-7
and the group of MCF-7 pretreated with HA. These
results suggest that the activation of the tumor invasive-
ness is dependent upon HA linkage to CD44st. Finally,
Figure 7 Secretion of HA inducting MMP-2 and MMP-9 protein. Cells treated with HA were incubated in serum free medium with or
without HA (100 μg/ml) for 24 h. The secretion of HA inducting MMP-2 and MMP-9 was detected by zymography. Normal human blood was
used as a positive control to identify MMP-9 and MMP-2 on gelatin zymograms.
Figure 8 CD44st and hyaluronan interaction leads to an increase in MCF-7/CD44st invasion capabilities. The invasive capability of the
tumor cells was assayed in the presence (+) and absence (-) of HA (100 μg/ml) for 24 h with transwell pretreated filters. Cells in the
pretreatment with CD44 blocking antibody groups were pretreated with anti-CD44 (20 μg/ml) for 3 h, and then treated with HA (100 μg/ml) for
24 h. ● P > 0.05, *P < 0.05.
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ways in HA-induced MMP-2 and MMP-9 secretion in
MCF-7/CD44st cells. These results indicated that MMP-
2 and MMP-9 secretion in MCF-7/CD44st cells is
potentially regulated by the HA-CD44st signaling path-
way. In addition, we demonstrated that CD44 blocking
antibody could block MMP-2 and MMP-9 secretion as
well as tumor invasion in MCF-7/CD44st cells.
The major causes of treatment failure in cancer are
the development of metastases and drug resistance. Cur-
rently, there is some evidence indicating that metastases
and multidrug resistance may have a functional link.
The extracellular matrix metalloproteinase inducer
(EMMPRIN) that is abundantly expressed on the surface
of tumor cells potentially stimulates the production of
matrix MMPs. MDR cells over-expressed EMMPRIN
compared to the parental sensitive cell lines, and were
capable of producing higher levels of MMP-1, MMP-2,
and MMP-9 [20]. In mammary cancer cells, the interac-
tion among HA, CD44, and EMMPRIN potentially
regulates the localization and function of the plasma
membrane transporter, as well as the tumor MDR [21].
CD44 and P-glycoprotein encoded by the MDR-1 gene
have a functional link, and collectively regulate malig-
nant biological phenotypes, tumor invasion, and MDR
[22]. Similarly, some recent studies also indicate that
both HA and CD44 are involved in chemotherapeutic
drug resistance in many cancers [23-27].
During tumor progression, blockage of the HA-CD44
signaling pathway may provide a new target that over-
comes multidrug resistance in breast and ovarian carci-
nomas [28]. The mitogen-activated protein kinase
(MAPK) signaling pathway is important to normal cells
as well as cancer cells. Inhibition of MAPK signaling
pathways could suppress renal cell carcinoma growth by
harming the tumor blood vessels [29]. HA-CD44 poten-
tially mediates the activation of ankyrin and Rho
GTPase as the tumor progresses, and thus are also
important markers for early diagnosis and evaluation of
disease prognosis [30].
Figure 9 Inhibition of MMP-2 and MMP-9 secretion and activation MAPK signaling pathway. A) MCF-7/CD44st cells were pretreated (+) or
unpretreated (-) with CD44 antibody, PD98059 and manumycin A, and then stimulated with HA (+) or without HA (-) for the indicated
concentrations and time periods. Conditioned medium samples were harvested and subjected to zymography (top panel). B) MCF-7/CD44st cells
were pretreated (+) or unpretreated (-) with CD44 antibody, PD98059 and manumycin A, for the indicated concentrations and time periods, and
then incubated with 100 μg/ml of HA (+) or without HA (+) for 0.5 h. Cells lysates were subjected to immunoblotting with anti-phospho-ERK
(bottom panel).
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Page 9 of 11The role of the expression of CD44 isoforms in tumor
progression has been widely studied in the last decade.
When CD44, HA, and heparanase are highly expressed
in breast cancer cells, they generate a microenvironment
that facilitates tumor progression and invasion [31]. The
phenotype of CD44+/CD24
- in breast cancer cells exhi-
bits a higher potential compared to other phenotypes of
breast cancer cell lines, however, this is not sufficient
evidence to elucidate the relationship with pulmonary
metastasis [32]. However, it has been previously
reported that the expression of CD44 potentially pre-
vents breast cancer cells from metastasizing. In an
experiment, the authors found that HA containing
material could inhibit the invasion of the CD44 positive
tumor cells. During cancer progression, HA-CD44
epithelial-stromal interaction potentially restrains tumor
metastasis [33]. As a result, some arguments remain
regarding the relationship between CD44 expression and
tumor progression and metastasis.
Conclusions
In summary, the results we present in this study suggest
that the novel CD44st gene, cloned from MCF7-/Adr
cells, plays an important role in the HA-dependent acti-
vation of MMP-2 and MMP-9, as well as the invasiveness
of MCF-7/CD44st cells. Furthermore, it appears that the
new CD44st gene and MDR-1 gene have some functional
links which influence the tumor’s multidrug resistance,
invasion, and metastasis all together. This lay a ground
work for further study. Our results potentially provide a
new therapeutic target for tumor invasion through the
regulation of the CD44st signal pathway. Finally, expres-
sion of CD44st could potentially be used as a dominant
selectable marker for the detection of the phenotype of
multidrug resistance and tumor cell invasion capabilities.
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